Brief Description: Concerning insulin affordability.

Sponsors: Senate Committee on Health & Long Term Care (originally sponsored by Senators Keiser, Van De Wege, Cleveland, Conway, Frockt, Hasegawa, Hunt, Lovick, Nguyen, Pedersen, Randall, Stanford and Wilson, C.).

Senate Committee on Health & Long Term Care
House Committee on Health Care & Wellness

Background: In 2020, the Legislature directed health plans, beginning January 1, 2021, to limit an enrollee's out-of-pocket expenses for insulin to $100 for a 30-day supply. The out-of-pocket limit is set to expire on January 1, 2023.

Summary: Beginning January 1, 2023, health plans must cap the total amount an enrollee is required to pay for a covered insulin drug at an amount not to exceed $35 per 30-day supply. This limit expires on January 1, 2024.

Votes on Final Passage:

<table>
<thead>
<tr>
<th></th>
<th>Senate</th>
<th>House</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>48</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>10</td>
</tr>
</tbody>
</table>

Effective: June 9, 2022

January 1, 2023 (Section 1)

This analysis was prepared by non-partisan legislative staff for the use of legislative members in their deliberations. This analysis is not part of the legislation nor does it constitute a statement of legislative intent.